[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sudden-sensorineural-hearing-loss-ssnhl\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sudden-sensorineural-hearing-loss-ssnhl":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,77,102,133,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100641829","cgm-guided-patch-pump-vs-basal-bolus-injection-for-steroid-induced-hyperglycemia-in-sudden-sensorineural-hearing-loss-ship-trial-100641829",false,"NCT07652528","CGM-guided Patch Pump vs Basal-Bolus Injection for Steroid-Induced Hyperglycemia in Sudden Sensorineural Hearing Loss: SHIP Trial","Steroid-induced Hyperglycemia Management With Insulin Patch Pump in Sudden Sensorineural Hearing Loss: a CGM-guided Exploratory Randomized Controlled Trial (SHIP Trial)","SHIP","Inclusion Criteria:\n\n1. Age ≥19 years\n2. Idiopathic SSNHL: ≥30 dB sensorineural hearing loss across ≥3 consecutive frequencies within 72 hours\n3. Affected ear PTA4 (mean of 0.5\u002F1\u002F2\u002F4 kHz) ≥40 dB HL (moderate or greater)\n4. Planned methylprednisolone 48 mg\u002Fday orally once in the morning\n5. At least one of: known T2DM; HbA1c 5.7-10.0% within 3 months; POC glucose ≥140 mg\u002FdL ×2 (≥2h apart, ≥1 postprandial) within 24h of steroid\n6. If on prior insulin: outpatient TDD ≤30 U\u002Fday\n7. Able to eat ≥2 meals\u002Fday, wear CGM and patch pump, use smartphone\n8. Willing to undergo 2-night inpatient admission (Day 1-3)\n9. Written informed consent\n\nExclusion Criteria:\n\n1. Type 1 DM, LADA, pancreatogenic DM, DKA\u002FHHS within 12 months, ketonuria at enrollment\n2. Enrollment POC ≥350 mg\u002FdL or immediate IV insulin requirement\n3. HbA1c ≥10.0%\n4. eGFR \\\u003C30 mL\u002Fmin\u002F1.73m² or dialysis\n5. Pregnancy\u002Fbreastfeeding; women of childbearing potential: positive urine hCG\n6. ICU, sepsis, NPO, TPN\u002Fenteral nutrition\n7. Severe hepatic failure (Child-Pugh C)\n8. Dexamethasone, divided-dose, or pulse steroids planned\n9. Prior CSII or AID device user\n10. Skin adhesive allergy precluding CGM or patch pump use\n11. Insufficient cognitive function for device or dosing table use\n12. Planned MRI requiring repeated CGM\u002Fpump removal\n13. PTA \\>70 dB (profound hearing loss requiring combined intratympanic steroid)","ALL","19 Years",{"count":20,"type":21},44,"ESTIMATED","INTERVENTIONAL",[24],"NA","This exploratory randomized controlled trial evaluates whether a CGM-guided temporary patch pump (CareLevo CSII) reduces glucocorticoid-induced hyperglycemia (GIH) compared to a Lantus-based basal-bolus injection (MDI) regimen in patients with sudden sensorineural hearing loss (SSNHL) and type 2 diabetes or prediabetes receiving high-dose systemic corticosteroids (methylprednisolone 48 mg\u002Fday).\n\nPatients with SSNHL are treated with high-dose oral corticosteroids as standard of care, which often causes significant postprandial hyperglycemia - particularly in patients with pre-existing diabetes or prediabetes. No randomized trial has investigated the optimal insulin delivery strategy for this specific clinical scenario.\n\nAll enrolled participants undergo a 2-night inpatient admission (Day 1-3) for safe insulin initiation and device education, followed by outpatient management (Day 4-14). All participants wear a CareSens Air continuous glucose monitor (CGM, 15-day sensor) throughout Day 1-14.\n\nParticipants meeting insulin activation criteria are randomized 1:1 to:\n\n* Arm A (CSII): CareLevo patch pump using a steroid-wave basal profile and carbohydrate-band meal bolus via the app's bolus calculator (CGM-integrated, IOB-adjusted)\n* Arm B (MDI): Insulin glargine U-100 (Lantus) qAM plus Fiasp prandial bolus via pen using a pre-printed dose table with identical carbohydrate-band algorithm\n\nBoth arms use identical glycemic targets, carbohydrate-band bolus algorithm (ICR\u002FISF identical), and correction rules. The primary difference is insulin delivery (patch pump vs. pen injection) and basal profile (steroid-wave CSII vs. flat glargine). The primary outcome is 24-hour CGM Time Above Range (TAR) \\>180 mg\u002FdL averaged over the 9-day high-dose steroid period (Day 1-9).",[27,28],"Sudden Sensorineural Hearing Loss (SSNHL)","Prediabetes \u002F Type 2 Diabetes",[30,31,32,33,34,35],"Sudden Sensorineural Hearing Loss","Glucocorticoid-Induced Hyperglycemia","Steroid-Induced Hyperglycemia","Continuous Glucose Monitoring","Insulin Pump Therapy","Patch Pump","NOT_YET_RECRUITING","2026-06-11",{"date":39,"type":40},"2026-06-17","ACTUAL",{"date":42,"type":21},"2026-08",{"date":44,"type":21},"2028-12",{"name":46,"class":47},"Hallym University","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100638394","acupuncture-therapy-for-sudden-sensorineural-hearing-loss-100638394","NCT07575334","Acupuncture Therapy for Sudden Sensorineural Hearing Loss","Acupuncture Combined With Glucocorticoids Therapy for Sudden Sensorineural Hearing Loss：A Multicenter Randomized Controlled Clinical Trial","SSNHL-Acu","Inclusion Criteria:\n\n* Age between 18 and 70 years;\n* Meets the diagnostic criteria for sudden sensorineural hearing loss (SSNHL): sudden, unexplained sensorineural hearing loss occurring within 72 hours, with a hearing threshold decrease of ≥30 dB in at least three consecutive frequencies among 250, 500, 1000, 2000, 4000, and 8000 Hz (reference: previous audiologic examination or same frequencies of the contralateral ear);\n* Unilateral SSNHL with self-perceived symmetrical hearing in both ears prior to the current episode (or supported by previous audiologic examination reports);\n* Time from symptom onset to enrollment and treatment initiation within 14 days;\n* Clear consciousness and logical responses, able to understand the scale items and complete the assessments;\n* Agrees to participate in the trial and signs a written informed consent form.\n\nExclusion Criteria:\n\n* Identifiable definite etiology after complete examination, including acoustic neuroma, cerebrovascular accident, trauma, Hunt syndrome, etc.;\n* History of hearing abnormality (affected ear) or balance dysfunction prior to the current episode (including previous SSNHL, vestibular migraine, Meniere's disease, benign paroxysmal positional vertigo, congenital\u002Fhereditary\u002Fsyphilitic hearing loss, otosclerosis, etc.);\n* Presence of diseases for which systemic corticosteroid therapy is clinically not recommended (e.g., poorly controlled or insulin-dependent diabetes mellitus, history of peptic ulcer, active infection or tuberculosis, history of hepatitis B or C, pancreatitis, severe osteoporosis, osteonecrosis, etc.);\n* Received systemic or local corticosteroid therapy for 10 days or more prior to enrollment;\n* Presence of other diseases (e.g., severe skin disorders) that preclude completion of acupuncture treatment;\n* Presence of severe organ dysfunction;\n* Received acupuncture treatment within the past 12 months;\n* Pregnant or breastfeeding women;\n* Other reasons deemed by the investigator as unsuitable for participation in this clinical study (e.g., high anticipated difficulty in completing follow-up, obvious low compliance, etc.).","18 Years","70 Years",{"count":59,"type":21},256,[24],"The goal of this multicenter, prospective, randomized controlled trial is to evaluate the efficacy and safety of acupuncture combined with corticosteroid therapy in treating sudden sensorineural hearing loss (SSNHL). The main questions it aims to answer are:\n\nDoes acupuncture combined with corticosteroids improve hearing recovery (pure tone audiometry, PTA) at 8 weeks compared with sham acupuncture combined with corticosteroids? Does this treatment improve secondary outcomes, including tinnitus, dizziness, sleep quality, anxiety, and quality of life? Researchers will compare acupuncture (experimental group) with sham acupuncture (control group) to determine the added therapeutic effect of acupuncture.\n\nParticipants will:\n\n1. Receive either real acupuncture or sham acupuncture 3 times per week for 4 weeks.\n2. Meanwhile, take oral prednisone (1 mg\u002Fkg\u002Fday, maximum 60 mg\u002Fday) for 7 days followed by a 7-day taper.\n3. Undergo hearing tests (PTA, word recognition scores), vestibular function tests, and complete validated questionnaires (SF-36, HADS, ISI, DHI, THI, and TCM symptom scales) at baseline and weeks 1, 2, 4, 8, and 12.\n4. Receive salvage intratympanic steroid injections if hearing does not improve sufficiently by day 14.",[27],[64,65],"acupuncture","Sudden sensorineural hearing loss (SSNHL)","RECRUITING","2026-05-03",{"date":69,"type":40},"2026-05-08",{"date":71,"type":40},"2026-04-13",{"date":73,"type":21},"2027-12-31",{"name":75,"class":47},"Eye & ENT Hospital of Fudan University",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":76},"100603250","phase-2-intracochlear-injection-of-glucocorticoid-100603250","NCT07134075","Intracochlear Injection of Glucocorticoid","Safety and Efficacy of Intracochlear Injection of Glucocorticoid Through the Round Window Membrane in Patients With Total Sudden Sensorineural Hearing Loss","Inclusion Criteria:\n\nAge between 18 and 65 years Unilateral idiopathic sudden sensorineural hearing loss greater than 95dB at the average of 4 frequencies (500 Hz, 1000 Hz, 2000 Hz and 4000 Hz) in PTA (contralateral hearing is less than 30dB) at the onset of sudden hearing loss Participant who were treated with standard treatment for 14 days, but no recovery was confirmed as type IV (final hearing level with hearing gain of ≤15 dB) at the end of the 14-day treatment\n\nExclusion Criteria:\n\nBilateral sudden sensorineural hearing loss Hearing loss with known causes (e.g., Meniere's disease, retrocochlear pathology, history of otologic surgery, perilymphatic fistula, barotrauma) History in the past 6 months of ototoxic treatment such as chemotherapy, use of loop diuretics, high dose aspirin, etc History of sudden sensorineural hearing loss within the past 2 years History of ischemic diseases (cerebral infarction, myocardial infarction, peripheral arterial obstructive disease) Neuropsychiatric disorders (epilepsy, Parkinson's disease, Alzheimer's disease, multiple sclerosis) Severe hepatic or renal insufficiency The CT diagnosis is \"abnormality of the round window niche\"","65 Years",{"count":86,"type":21},150,[88],"PHASE2","This study is a prospective, randomized pilot study. To verify safety and efficacy of intracochlear injection of glucocorticoid through the round window membrane in patients with total sudden sensorineural hearing loss safety and efficacy in total sudden sensorineural hearing loss patients as an early salvage therapy.",[27],[92,93],"intracochlear injection","glucocorticoid","2025-08-14",{"date":96,"type":40},"2025-08-21",{"date":98,"type":21},"2025-08-25",{"date":100,"type":21},"2027-08-01",{"name":75,"class":47},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":76},"100592743","inner-ear-support-oral-capsule-in-patients-with-sudden-sensorineural-hearing-loss-100592743","NCT06997406","'Inner Ear Support' Oral Capsule in Patients With Sudden Sensorineural Hearing Loss","Explore the Benefit of 'Inner Ear Support' Oral Capsule in Patients With Sudden Sensorineural Hearing Loss - A Randomized, Open-label, Single-center Study","Inclusion Criteria:\n\n* Patients aged between 18 and 75 years\n* Patients diagnosed with sudden sensorineural hearing loss as determined by the principal or sub-investigator\n* Average hearing threshold in the affected ear ≥ 60 dB\n* Initiation of treatment within two weeks of hearing loss onset\n\nExclusion Criteria:\n\n* Patients with congenital or hereditary hearing loss\n* Patients with fluctuating hearing loss\n* Patients currently participating in other interventional treatments for sudden hearing loss\n* Patients who have undergone surgery on the affected ear\n* Patients with neurological or psychiatric disorders\n* Patients with heart failure or ischemic heart disease\n* Patients with immunodeficiency\n* Patients with vestibular schwannoma (acoustic neuroma)\n* Patients with other internal medical conditions deemed by the investigator to potentially interfere with the study conduct or outcomes\n* Pregnant patients\n* Patients with a known allergy to the investigational product\n* Patients currently using acetylcysteine or products containing ginkgo biloba extract\n* Patients with autoimmune diseases or currently receiving immunosuppressive therapy","75 Years",{"count":111,"type":21},80,[24],"Sudden sensorineural hearing loss (SSNHL) is a medical condition where people experience rapid hearing loss, usually in one ear, over a short period of time (typically within 72 hours). It can affect people of any age, though it is more common among adults aged 40 to 60. In many cases, the exact cause remains unknown, but possible reasons include viral infections, immune-related problems, and reduced blood circulation to the inner ear. Along with hearing loss, many patients may also experience tinnitus (ringing in the ears) or dizziness.\n\nThe standard treatment for SSNHL often involves steroids, sometimes combined with hyperbaric oxygen therapy. However, the effectiveness of these treatments varies, and many patients do not fully recover their hearing. This study aims to explore whether an additional supplement-'Inner ear support' oral capsule-can improve hearing outcomes and relieve associated symptoms in patients with SSNHL.\n\nThe study will involve 80 participants who are randomly assigned to two groups. Both groups will receive standard treatment (including steroids and possibly hyperbaric oxygen therapy), but only the test group will take the 'Inner ear support' capsule twice daily for 28 days. Participants will be followed and evaluated over a period of 196 days through hearing tests and symptom questionnaires.\n\n'Inner ear support' is a commercially available nutritional supplement that includes FB-1603 (an extract from Arthrospira maxima), GABA, gamma-oryzanol, and sesamin. Previous research has shown that FB-1603 and its active component, C-phycocyanin, have anti-inflammatory, antioxidant, and nerve-protective effects. Animal studies suggest it may help reduce tinnitus and prevent hearing deterioration.\n\nThis clinical trial is designed to evaluate whether 'Inner ear support' can enhance hearing recovery, improve tinnitus and dizziness symptoms, and be safely used as an additional treatment in patients with sudden hearing loss. All participants will be monitored for any potential side effects during the study period.\n\nThe ultimate goal of this study is to determine whether' Inner ear support' could become a helpful addition to current treatment methods for SSNHL, improving patient outcomes and quality of life.",[27,115],"Tinnitus",[30,117,118,115,119,120,121,122],"SSNHL","C-phycocyanin","Hearing Recovery","Inner Ear Support","Arthrospira","herbal medicine","2025-05-21",{"date":125,"type":40},"2025-05-30",{"date":127,"type":21},"2025-06-01",{"date":129,"type":21},"2026-06-30",{"name":131,"class":132},"Far East Bio-Tec Co., Ltd","INDUSTRY",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":109,"enrollmentInfo":140,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":150,"leadSponsor":152,"locationsCount":76},"100579046","effect-of-hyperbaric-oxygen-therapyhbot-on-patients-with-sudden-sensorineural-hearing-lossssnhl-and-coagulation-function-100579046","NCT06819202","Effect of Hyperbaric Oxygen Therapy(HBOT) on Patients With Sudden Sensorineural Hearing Loss(SSNHL) and Coagulation Function","Effect of Hyperbaric Oxygen Therapy on Patients With Sudden Sensorineural Hearing Loss and Coagulation Function","Inclusion Criteria:\n\n* Meet the diagnostic criteria for sudden deafness in the American Academy of Otolaryngology Head and Neck Surgery 2019 Clinical Practice Guidelines for Sudden Deafness;\n* Aged 18-75 years old;\n* Patients with unilateral sudden deafness for the first time, and the onset time is less than 2 weeks.\n\nExclusion Criteria:\n\n* Patients with other ear diseases, such as auditory trauma, barotrauma, retrocochlear disease, bilateral hearing loss, history of chronic otitis media in the same ear, and history of surgery in the same ear;\n* Patients with serious primary diseases such as heart, liver, kidney dysfunction and hematopoietic system diseases;\n* Pregnant and nursing patients;\n* Accompanied by serious mental illness;\n* Patients with incomplete clinical data.",{"count":141,"type":21},1309,"OBSERVATIONAL","The objective of this observational study was to understand the effect of HBO on patients with SSNHL and its association with coagulation function and prognosis.\n\nThe main question it aims to answer is whether HBO therapy can improve outcomes and coagulation function in patients with SSNHL.\n\nThe prognosis of SSNHL patients receiving HBO and SSNHL patients not receiving HBO were compared",[27,145],"Hyperbaric Oxygen Therapy","2025-05-13",{"date":148,"type":40},"2025-05-14",{"date":127,"type":21},{"date":151,"type":21},"2025-12-01",{"name":153,"class":47},"Sun Yuting",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":76},"100583613","phase-4-intratympanic-injection-of-dexamethasone-with-hyaluronic-acid-in-treatment-of-sudden-sensorineural-hearing-loss-100583613","NCT06878599","Intratympanic Injection of Dexamethasone With Hyaluronic Acid in Treatment of Sudden Sensorineural Hearing Loss","Inclusion Criteria:\n\n1. Adult patients (aged 18 and over)\n2. Patients with sudden sensory neural hearing loss (SSNHL)\n\nExclusion Criteria:\n\n1. Patients with middle or external ear pathology.\n2. Patient with history of traumatic skull base fracture.\n3. Patients with previous ear surgery.\n4. Patients with other neurological symptoms or signs (Other cranial nerves affection).",{"count":161,"type":21},70,[163],"PHASE4","* To evaluate efficacy of intratympanic injection of dexamethasone and hyaluronic acid mixture as a treatment modality in cases of sudden sensorineural hearing loss (SSNHL).\n* To compare outcomes of intratympanic injection of dexamethasone and hyaluronic acid mixture to dexamethasone alone in treatment of SSNHL.",[27],[167,168,117,30],"Hyaluronic acid","Dexamethasone","2025-03-13",{"date":171,"type":40},"2025-03-17",{"date":173,"type":21},"2025-05-01",{"date":175,"type":21},"2028-10",{"name":177,"class":47},"Assiut University"]